Palantir cofounder wants a 30,000 monkey farm in the US — because AI jacked up macaque prices by 700% in seven years

Rapid drug discovery using AI's assistance is adding pressure to an already restricted macaque supply A US startup plans to breed 30,000 monkeys over two decades China's export ban cut off a major source of American research animals Artificial intelligence is creating new demands for pharmaceutical

<![CDATA[ <article> <ul><li><strong>Rapid drug discovery using AI's assistance is adding pressure to an already restricted macaque supply</strong></li><li><strong>A US startup plans to breed 30,000 monkeys over two decades</strong></li><li><strong>China's export ban cut off a major source of American research animals</strong></li></ul><p>Artificial intelligence is creating new demands for pharmaceutical research, increasing pressure on all kinds of resources needed to develop and test potential treatments - including animal test subjects.</p><p>Macaques, commonly used in medical experiments, have become considerably more expensive, with reported prices rising from approximately $3,000 in 2019 to more than $20,000 today.</p><p>Now , Palantir cofounder Joe Lonsdale is reportedly supporting Safer Human Medicine, a startup seeking to establish a large-scale breeding facility in the US.</p><h2 id="rising-demand-meets-restricted-monkey-supplies">Rising demand meets restricted monkey supplies</h2><p>The proposed facility would eventually accommodate 30,000 monkeys, with the company planning to increase its breeding population gradually over approximately 20 years.</p><p>Its initial stock would comprise between 500 and 1,000 macaques obtained from breeding facilities across Asia.</p><p>The company intends to expand domestic production and reduce American laboratories’ dependence on imported animals for pharmaceutical research and testing.</p><p>Artificial intelligence has intensified the pressure by enabling researchers to develop potential medicines more rapidly and generate more drug candidates for testing.</p><p>Each promising candidate may then require laboratory studies to assess toxicity, safety and biological effects before human clinical trials.</p><p>Some experimental treatments require animal studies before human trials, and macaques are frequently selected because of their biological similarities to humans.</p><p>However, the supply problem predates the recent expansion of artificial intelligence applications within pharmaceutical research and drug discovery programmes.</p><p>China, previously responsible for approximately 60% of America's laboratory monkey imports, prohibited exports in 2020, forcing researchers to seek alternative suppliers.</p><p>American laboratories subsequently turned to Cambodia, but investigations in 2022 uncovered allegations involving wild-caught monkeys falsely represented as captive-bred animals.</p><h2 id="breeding-limitations-and-animal-welfare-concerns">Breeding limitations and animal welfare concerns</h2><p>Expanding captive populations is not an immediate solution because female macaques generally reach reproductive maturity around four years of age.</p><p>Each female typically produces one offspring annually, limiting how quickly breeding operations can increase their populations to meet laboratory requirements.</p><p>China now reportedly charges approximately $26,000 per macaque, roughly nine times the price recorded in 2019.</p><p>American laboratories reportedly import approximately 20,000 monkeys annually, leaving researchers exposed to international supply restrictions and substantial procurement expenses.</p><p>Safer Human Medicine's proposed operation would therefore require considerable time before its intended population could supply a significant share of domestic demand.</p><p>Nevertheless, the plan has already attracted criticism from animal welfare advocates concerned about keeping thousands of primates for experimental purposes.</p><p>A critic on X described the proposed breeding operation as “morally indefensible,” and others have called for judicial intervention against what they consider animal abuse.</p><p>Their objections could lead to legal challenges, potentially delaying construction, breeding activities, or the company's plans to establish domestic production capacity.</p><p>The eventual progress of this project will depend not only on breeding capacity and commercial demand, but also on regulatory scrutiny and potential court proceedings.</p><p>Via <a href="https://x.com/itsolelehmann/status/2115536445159129483" target="_blank" rel="nofollow">Ole Lehmann on X</a></p><figure class="van-image-figure inline-layout" data-bordeaux-image-check="" ><div class='image-full-width-wrapper'><div class='image-widthsetter' style="max-width:676px;"><p class="vanilla-image-block" style="padding-top:31.51%;"><img id="diM9tpwF2Lz85R8q85CT78" name="tr-g_news" alt="Google logo on a black background next to text reading 'Click to follow TechRadar'" src="https://cdn.mos.cms.futurecdn.net/diM9tpwF2Lz85R8q85CT78-1920-80.jpg" mos="" align="middle" fullscreen="" width="676" height="213" attribution="" endorsement="" class="inline" /></p></div></div></figure> </article> ]]>